Izrael -
hebrejščina -
Ministry of Health
סרדלגה
sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat
Izrael -
hebrejščina -
Ministry of Health
פירמגון 120 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה להכנת תמיסה לזריקה - degarelix as acetate 120 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פירמגון 80 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה להכנת תמיסה לזריקה - degarelix as acetate 80 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פנאפט טבליות 10 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 10 mg - iloperidone
Izrael -
hebrejščina -
Ministry of Health
פנאפט טבליות 12 מג'
megapharm ltd - iloperidone - טבליה - iloperidone 12 mg - iloperidone
Izrael -
hebrejščina -
Ministry of Health
פירמגון 120 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה וממס להכנת תמיסה לאינפוזיה - degarelix as acetate 120 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פירמגון 120 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה וממס להכנת תמיסה להזרקה - degarelix as acetate 120 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פירמגון 80 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה וממס להכנת תמיסה להזרקה - degarelix as acetate 80 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פירמגון 80 מג
ferring pharmaceuticals ltd - degarelix as acetate - אבקה וממס להכנת תמיסה להזרקה - degarelix as acetate 80 mg - degarelix
Izrael -
hebrejščina -
Ministry of Health
פלויקס 75 מג
sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid